IRONWOOD PHARMACEUTICALS INC annual report, FY2012

Full document

Ironwood Pharmaceuticals, Inc. — 2012 Form 10-K

Business context and reporting period. This annual report covers the fiscal year ended December 31, 2012; the filing also provides unaudited fourth-quarter results. Ironwood is a pharmaceutical company whose lead and only product with clinical proof of concept is linaclotide. The FDA approved LINZESS for adult IBS-C and CIC in August 2012, and U.S. commercial sales with Forest began in December. The European Commission approved Constella for adult IBS-C in November; partner Almirall expected launches in some European countries in the first half of 2013.

Financial performance and liquidity

  • Revenue: Collaborative arrangements revenue was $150.2 million in 2012, up 128.1% from $65.9 million in 2011. The increase chiefly reflected Forest milestones and AstraZeneca collaboration revenue, rather than a full year of product sales.
  • Profit and margins: Operating loss was $72.8 million, versus $66.1 million in 2011; net loss was $72.6 million, versus $64.9 million. Basic and diluted loss per share was $0.68, compared with $0.65. Operating loss was approximately 48% of revenue. The company reported a $47.6 million net profit in Q3, but losses in the other quarters; the filing attributes the quarterly pattern to collaboration revenue and milestone timing.
  • Costs: Research and development expense increased 31.8% to $113.5 million. Selling, general and administrative expense roughly doubled to $92.5 million, primarily reflecting commercial-launch hiring and infrastructure. Collaboration expense was $16.0 million, including Ironwood’s share of U.S. launch-period losses.
  • Cash flow: Operating cash use was $69.6 million, compared with $75.2 million in 2011. Investing activities provided $30.1 million, mainly from investment maturities and sales; financing activities provided $89.0 million, mainly from the February 2012 equity offering. Cash and cash equivalents increased $49.4 million during the year.
  • Liquidity and balance sheet: At year-end, cash, cash equivalents and available-for-sale securities totaled $168.2 million; working capital excluding deferred revenue was $132.9 million. Total assets were $229.9 million and stockholders’ equity was $144.1 million. The company had $0.6 million of capital lease obligations and no long-term debt recorded at December 31, 2012.
  • Subsequent financing: On January 4, 2013, Ironwood issued $175.0 million of notes, receiving approximately $167.3 million net. The notes bear 11% annual interest; quarterly payments begin in June 2013, with principal payments expected to begin in March 2014 and payments linked to U.S. LINZESS sales, subject to a minimum interest payment.

Changes versus prior periods

  • Revenue rose substantially, primarily from $85.0 million in Forest milestones following FDA approval and $24.7 million recognized for the AstraZeneca China license. In 2011, Forest NDA-acceptance milestones totaled $20.0 million.
  • Total costs and expenses increased 68.9% to $223.0 million, led by launch-related SG&A and higher R&D spending. Despite higher revenue, the operating loss widened by $6.6 million.
  • Cash and short-term investments totaled $168.2 million at year-end 2012, compared with $164.0 million a year earlier. The 2012 figure excludes the net proceeds from the January 2013 notes, which were not on the year-end balance sheet.
  • Deferred revenue fell to $21.4 million from $57.4 million, reflecting recognition of collaboration revenue as development periods ended and milestones were earned.

Outlook, commentary, and principal risks

  • Management expected substantial losses and R&D spending to continue for the foreseeable future, and said it could not predict when, or if, the company would achieve profitability or positive operating cash flow. It believed year-end cash plus the subsequent debt proceeds would fund projected operations for at least 12 months, while cautioning that actual needs could be greater.
  • LINZESS commercial success depends on physician and patient adoption, reimbursement and access, launch execution with Forest, and the product’s safety profile. Ironwood’s U.S. economics are a 50% share of net profits or losses after specified product and commercialization costs.
  • The most common adverse reaction reported in trials was diarrhea; severe diarrhea occurred in 2% of linaclotide-treated patients. The U.S. label includes a boxed warning for pediatric use: contraindicated up to age six and physicians are cautioned to avoid use from ages six through 17. Required post-approval studies include pediatric-related nonclinical work and studies concerning breast milk and antibodies.
  • Ironwood relies on external manufacturers and partners for production, distribution and commercialization. Manufacturing capacity, quality or supply interruptions, partner execution, pricing and reimbursement, competition, regulatory requirements, and the outcome of further trials could adversely affect results.
  • Patent risk includes a third-party-requested USPTO reexamination of a patent covering a group of peptides that includes LINZESS. The company stated that other linaclotide patents and five-year FDA exclusivity also provide protection.
  • Potential future milestone payments to third parties are substantial and contingent: the filing reports approximately $364.0 million under certain agreements and up to $114.5 million per product under one collaboration, in addition to royalties. Contractual obligations reported at year-end totaled $122.8 million, chiefly operating leases and commercial supply commitments; the table excludes interest and contingent milestone payments.
  • Ironwood reported no material legal proceedings in Item 3 and no unresolved SEC staff comments. Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2012.

Key facts for investors to verify

  • Whether LINZESS sales, net of shared launch costs, can grow enough to reduce Ironwood’s operating losses and support debt payments.
  • The commercial launch pace, pricing and reimbursement for Constella in Europe and progress in China and other partner territories.
  • Post-marketing study results, adverse-event trends, and any resulting changes to LINZESS labeling or use.
  • Manufacturing capacity and supply reliability, and whether partners meet development and commercialization commitments.
  • The notes’ detailed payment, covenant, collateral and redemption terms, and how sales-linked payments affect liquidity.
  • The status and implications of the patent reexamination and the usability of tax-loss and tax-credit carryforwards subject to ownership-change limits.